SCPS (Scopus BioPharma) YoY EBITDA Growth: 52.87% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Scopus BioPharma YoY EBITDA Growth?

Scopus BioPharma SCPS YoY EBITDA Growth is 52.87% as of Jun. 2023.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Scopus BioPharma's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was 52.87%.

Scopus BioPharma's EBITDA per Share for the three months ended in Jun. 2023 was $-0.07.

Scopus BioPharma YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma YoY EBITDA Growth Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
Get a 7-Day Free Trial 0.00 -291.30 -322.22 -99.61 63.41

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.39 -20.00 74.18 60.18 52.87

Scopus BioPharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Scopus BioPharma's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-0.555--1.517)/ | -1.517 |
=63.41 %

Scopus BioPharma's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (Q: Jun. 2023 )
=(EBITDA per Share (Q: Jun. 2023 )-EBITDA per Share (Q: Jun. 2022 )) / | EBITDA per Share (Q: Jun. 2022 )) |
=(-0.074--0.157)/ | -0.157 |
=52.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 52.87% mean?
Scopus BioPharma (SCPS) has a YoY EBITDA Growth of 52.87% as of Jun. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scopus BioPharma and its competitors.
Is Scopus BioPharma's YoY EBITDA Growth too high?
Scopus BioPharma's current YoY EBITDA Growth is 52.87%.
How does Scopus BioPharma's YoY EBITDA Growth compare to AMPE and DRMA?
Scopus BioPharma's YoY EBITDA Growth of 52.87% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scopus BioPharma and its competitors. Scopus BioPharma's current YoY EBITDA Growth is 52.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current YoY EBITDA Growth of 52.87%. The current YoY EBITDA Growth is 52.87%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current YoY EBITDA Growth is 52.87% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.